THE US baby formula crisis has boosted profits at Britain’s Reckitt Benckiser and helped it grab the top spot in a US$5.8bil (RM25.4bil)-a-year market.

The challenge now will be to stay there. With the business reportedly up for sale, there’s even more at stake.

Reckitt has ramped up production of its Enfamil formula since US rival Abbott Laboratories in February recalled dozens of products in the United States after customers complained of infants contracting bacterial infections.